Report overview
The tumor cells which have shed into lymphatic system and circulated over the body through blood circulation are called as circulating tumor cells. Circulating tumor cells may comprise seeds for metastasis. Stem cells are the type of cells that can differentiate into specialized cells and have the capacity of self-renewal. Cancer stem cells are the cancer cells that possess the characteristics of normal stem cells. Cancer stem cells are said to be responsible for relapse of cancers in patients. There is a growing interest in these two cell types due to their fundamental biological and clinical implications. Circulating tumor cells and cancer stem cells are an important element in order to understand cancer related mechanism and to find a cure from all type of cancers. These cells can be used for detecting of metastasis and the patients who are at a higher risk of cancer relapse.
This report contains market size and forecasts of Circulating Tumor Cells and Cancer Stem Cells in Global, including the following market information:
Global Circulating Tumor Cells and Cancer Stem Cells Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Circulating Tumor Cells and Cancer Stem Cells market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cell Enrichment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Circulating Tumor Cells and Cancer Stem Cells include QIAGEN Hannover, AVIVA Biosciences, Epic Sciences, ApoCell, Cynvenio Biosystems, Fluxion Biosciences, Rarecells, Janssen Diagnostics and CellTraffix, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Circulating Tumor Cells and Cancer Stem Cells companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Circulating Tumor Cells and Cancer Stem Cells Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Circulating Tumor Cells and Cancer Stem Cells Market Segment Percentages, by Type, 2021 (%)
Cell Enrichment
Cell Detection
CTC Analysis
Global Circulating Tumor Cells and Cancer Stem Cells Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Circulating Tumor Cells and Cancer Stem Cells Market Segment Percentages, by Application, 2021 (%)
Hospital
NSC
Medical Research Institute
Global Circulating Tumor Cells and Cancer Stem Cells Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Circulating Tumor Cells and Cancer Stem Cells Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Circulating Tumor Cells and Cancer Stem Cells revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Circulating Tumor Cells and Cancer Stem Cells revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
QIAGEN Hannover
AVIVA Biosciences
Epic Sciences
ApoCell
Cynvenio Biosystems
Fluxion Biosciences
Rarecells
Janssen Diagnostics
CellTraffix
Silicon Biosystems
Advanced Cell Diagnostics
